Your browser doesn't support javascript.
loading
Improvement in the 95-95-95 Targets Is Accompanied by a Reduction in Both the Human Immunodeficiency Virus Transmission Rate and Incidence in China.
Ye, Jingrong; Lan, Yun; Wang, Juan; Feng, Yi; Lin, Yi; Zhou, Ying; Liu, Jinjin; Yuan, Dan; Lu, Xinli; Guo, Weigui; Zheng, Minna; Song, Xiao; Zhou, Quanhua; Yang, Hong; Zheng, Chenli; Guo, Qi; Yang, Xiaohui; Yang, Kai; Zhang, Lincai; Ge, Zhangwen; Liu, Lifeng; Yu, Fengting; Han, Yang; Huang, Huihuang; Hao, Mingqiang; Chen, Qiang; Ling, Xuemei; Ruan, Yuhua; Dong, Yuan; Zhou, Chang; Liu, Xuangu; Bai, Jianyun; Tong, Xue; Gao, Ya; Yang, Zhengrong; Wang, Ao; Wei, Wei; Mei, Fanghua; Qiao, Ruijuan; Luo, Xinhua; Huang, Xiaojie; Chen, Jing; Hu, Fengyu; Shen, Xin; Tan, Wei; Tu, Aixia; Zhang, Xinhui; He, Shufang; Ning, Zhen; Fan, Jixiang.
Afiliação
  • Ye J; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Control and Prevention (CDC), Beijing Academy of Preventive Medicine, Beijing.
  • Lan Y; Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou.
  • Wang J; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Control and Prevention (CDC), Beijing Academy of Preventive Medicine, Beijing.
  • Feng Y; Division of Virology and Immunology, State Key Laboratory for Infectious Disease Prevention and Control and National Center for AIDS/STD Prevention and Control, China CDC, Beijing.
  • Lin Y; Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC.
  • Zhou Y; Shanghai Institutes of Preventive Medicine.
  • Liu J; Shanghai Center for AIDS Research, Shanghai.
  • Yuan D; Institute of AIDS/STD Control and Prevention, Jiangsu CDC, Nanjing.
  • Lu X; Center for Translational Medicine, Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, The Sixth People's Hospital of Zhengzhou), Zhengzhou.
  • Guo W; Center for AIDS/STD Control and Prevention, Sichuan CDC, Chengdu.
  • Zheng M; Department of AIDS Research, Hebei Key Laboratory of Pathogen and Epidemiology of Infectious Disease, Hebei CDC, Shijiazhuang.
  • Song X; Institute of HIV/AIDS Prevention and Control, Beihai CDC, Beihai.
  • Zhou Q; Department of STDs/AIDS Control and Prevention, Tianjin CDC, Tianjin.
  • Yang H; Institute for HIV/AIDS and STD Prevention and Control, Heilongjiang CDC, Harbin.
  • Zheng C; Institute of Microbiology, Chongqing CDC, Chongqing.
  • Guo Q; STD/AIDS Prevention and Control Institute, Inner Mongolia CDC (Inner Mongolia Academy of Preventive Medicine), Hohhot.
  • Yang X; Department of HIV/AIDS Control and Prevention, Shenzhen CDC, Shenzhen.
  • Yang K; Virology Laboratory, Jilin CDC, Changchun.
  • Zhang L; Institute for HIV/AIDS and STD Prevention and Control, Fuyang CDC, Fuyang.
  • Ge Z; Hubei CDC, Wuhan.
  • Liu L; Institute for HIV/AIDS and STD Prevention and Control, Gansu CDC, Lanzhou.
  • Yu F; Guizhou Provincial People's Hospital, Affiliated Hospital of Guizhou University, Guiyang.
  • Han Y; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing.
  • Huang H; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing.
  • Hao M; Department of Infectious Disease, Peking Union Medical College Hospital, Beijing.
  • Chen Q; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing.
  • Ling X; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Control and Prevention (CDC), Beijing Academy of Preventive Medicine, Beijing.
  • Ruan Y; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Control and Prevention (CDC), Beijing Academy of Preventive Medicine, Beijing.
  • Dong Y; Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou.
  • Zhou C; Division of Virology and Immunology, State Key Laboratory for Infectious Disease Prevention and Control and National Center for AIDS/STD Prevention and Control, China CDC, Beijing.
  • Liu X; Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC.
  • Bai J; Shanghai Institutes of Preventive Medicine.
  • Tong X; Shanghai Center for AIDS Research, Shanghai.
  • Gao Y; Center for AIDS/STD Control and Prevention, Sichuan CDC, Chengdu.
  • Yang Z; Institute of HIV/AIDS Prevention and Control, Beihai CDC, Beihai.
  • Wang A; Department of STDs/AIDS Control and Prevention, Tianjin CDC, Tianjin.
  • Wei W; Institute for HIV/AIDS and STD Prevention and Control, Heilongjiang CDC, Harbin.
  • Mei F; STD/AIDS Prevention and Control Institute, Inner Mongolia CDC (Inner Mongolia Academy of Preventive Medicine), Hohhot.
  • Qiao R; Department of HIV/AIDS Control and Prevention, Shenzhen CDC, Shenzhen.
  • Luo X; Virology Laboratory, Jilin CDC, Changchun.
  • Huang X; Institute for HIV/AIDS and STD Prevention and Control, Fuyang CDC, Fuyang.
  • Chen J; Hubei CDC, Wuhan.
  • Hu F; Institute for HIV/AIDS and STD Prevention and Control, Gansu CDC, Lanzhou.
  • Shen X; Guizhou Provincial People's Hospital, Affiliated Hospital of Guizhou University, Guiyang.
  • Tan W; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing.
  • Tu A; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Control and Prevention (CDC), Beijing Academy of Preventive Medicine, Beijing.
  • Zhang X; Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou.
  • He S; Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC.
  • Ning Z; Shanghai Institutes of Preventive Medicine.
  • Fan J; Shanghai Center for AIDS Research, Shanghai.
J Infect Dis ; 2024 Aug 26.
Article em En | MEDLINE | ID: mdl-39186695
ABSTRACT

BACKGROUND:

In 2016, China has implemented the World Health Organization's "treat all" policy. We aimed to assess the impact of significant improvements in the 95-95-95 targets on population-level human immunodeficiency virus (HIV) transmission dynamics and incidence.

METHODS:

We focused on 3 steps of the HIV care continuum diagnosed, on antiretroviral therapy, and achieving viral suppression. The molecular transmission clusters were inferred using HIV-TRACE. New HIV infections were estimated using the incidence method in the European Centre for Disease Prevention and Control HIV Modelling Tool.

RESULTS:

Between 2004 and 2023, the national HIV epidemiology database recorded 2.99 billion person-times of HIV tests and identified 1 976 878 new diagnoses. We noted a roughly "inverted-V" curve in the clustering frequency, with the peak recorded in 2014 (67.1% [95% confidence interval, 63.7%-70.5%]), concurrent with a significant improvement in the 95-95-95 targets from 10-13-<71 in 2005 to 84-93-97 in 2022. Furthermore, we observed a parabolic curve for a new infection with the vertex occurring in 2010.

CONCLUSIONS:

In general, it was suggested that the improvements in the 95-95-95 targets were accompanied by a reduction in both the population-level HIV transmission rate and incidence. Thus, China should allocate more effort to the first "95" target to achieve a balanced 95-95-95 target.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos